SCHEMBL2033711

SCHEMBL2033711

CNC(=O)c1ccccc1Nc1nc(Nc2cccc(CP(C)(C)=O)c2)ncc1C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKMYT1 Q99640 1/20 0.60
▸ CDC7 O00311 1/20 0.57
▸ ROCK2 O75116 1/20 0.57
▸ MAP4K4 O95819 1/20 0.57
▸ PIM1 P11309 1/20 0.57
▸ PRKACA P17612 1/20 0.57
▸ CDK7 P50613 1/20 0.57
▸ CDK9 P50750 1/20 0.57
▸ HIPK2 Q9H2X6 1/20 0.57
▸ IRAK4 Q9NWZ3 1/20 0.57
▸ PTK2 Q05397 14/20 0.54
▸ KDR P35968 2/20 0.53
▸ JAK2 O60674 1/20 0.53
▸ NTRK1 P04629 1/20 0.53
▸ TYK2 P29597 1/20 0.53
▸ JAK3 P52333 1/20 0.53
▸ PTK2B Q14289 1/20 0.53
▸ NTRK3 Q16288 1/20 0.53
▸ NTRK2 Q16620 1/20 0.53
▸ MET P08581 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2031650 0.92 PKMYT1 (0.58) PKMYT1CDC7ROCK2MAP4K4PIM1
SCHEMBL2051845 0.90 PTK2 (0.62) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL12586455 0.87 CDC7 (0.60) PKMYT1CDC7ROCK2MAP4K4PIM1
SCHEMBL2637548 0.83 PTK2 (0.62) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL25241734 0.83 PTK2 (0.67) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL30467307 0.83 PTK2 (0.67) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL31653644 0.82 PTK2 (0.65) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL2029802 0.82 PTK2 (0.65) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL2038520 0.82 PTK2 (0.61) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL19725105 0.81 CDC7 (0.57) CDC7ROCK2MAP4K4PIM1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438056-B1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS LLC (US) 2017-12-20 — — EP claimed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US claimed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US claimed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US claimed
EP-2438056-B1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS LLC (US) 2017-12-20 — — EP disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS PKMYT1 247/4885CDC7 1045/4885ROCK2 1990/4885
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS PKMYT1 247/4885CDC7 1045/4885ROCK2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback